Turn Therapeutics Inc NASDAQ:TTRX is expected to report resultson July 6 (estimated) for the period ending June 30 2026
LSEG's mean analyst estimate for Turn Therapeutics Inc is for a loss of 3 cents per share.
The one available analyst rating on the shares is "buy".
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Turn Therapeutics Inc is $6.15, about 13.6% below its last closing price of $7.12
Reuters
Turn Therapeutics Inc expected to post a loss of 3 cents a share - Earnings Preview
Turn Therapeutics Inc NASDAQ:TTRX is expected to report resultson July 6 (estimated) for the period ending June 30 2026LSEG's mean analyst estimate for Turn Therapeutics Inc is f